BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31952912)

  • 1. Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions.
    Kimoto E; Obach RS; Varma MVS
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):18-29. PubMed ID: 31952912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
    Varma MV; El-Kattan AF
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transporter-enzyme interplay and the hepatic drug clearance: what have we learned so far?
    Alluri RV; Li R; Varma MVS
    Expert Opin Drug Metab Toxicol; 2020 May; 16(5):387-401. PubMed ID: 32228316
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytochrome-P450-Mediated Drug
    Steyn SJ; Varma MVS
    Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When Does the Rate-Determining Step in the Hepatic Clearance of a Drug Switch from Sinusoidal Uptake to All Hepatobiliary Clearances? Implications for Predicting Drug-Drug Interactions.
    Patilea-Vrana GI; Unadkat JD
    Drug Metab Dispos; 2018 Nov; 46(11):1487-1496. PubMed ID: 30115647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
    El-Kattan AF; Varma MV; Steyn SJ; Scott DO; Maurer TS; Bergman A
    Pharm Res; 2016 Dec; 33(12):3021-3030. PubMed ID: 27620173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
    Li R; Barton HA; Varma MV
    Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).
    Varma MV; Steyn SJ; Allerton C; El-Kattan AF
    Pharm Res; 2015 Dec; 32(12):3785-802. PubMed ID: 26155985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.
    El-Kattan AF; Varma MVS
    Drug Metab Dispos; 2018 May; 46(5):729-739. PubMed ID: 29496721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay.
    Matsunaga N; Fukuchi Y; Imawaka H; Tamai I
    Drug Metab Dispos; 2018 May; 46(5):680-691. PubMed ID: 29352067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of Drug or Food with Drug Transporters in Intestine and Liver.
    Nakanishi T; Tamai I
    Curr Drug Metab; 2015; 16(9):753-64. PubMed ID: 26630906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay of transporters and enzymes in drug and metabolite processing.
    Pang KS; Maeng HJ; Fan J
    Mol Pharm; 2009; 6(6):1734-55. PubMed ID: 19891494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.
    Kimoto E; Mathialagan S; Tylaska L; Niosi M; Lin J; Carlo AA; Tess DA; Varma MVS
    J Pharmacol Exp Ther; 2018 Nov; 367(2):322-334. PubMed ID: 30135178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
    Chu X; Chan GH; Evers R
    J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
    Langer O
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
    Feng B; Varma MV
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data.
    Zhao YS; Chen F; Li L
    Curr Drug Metab; 2014; 15(8):767-90. PubMed ID: 25705906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance.
    Liang X; Lai Y
    Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):869-886. PubMed ID: 33793347
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.
    Bohnert T; Patel A; Templeton I; Chen Y; Lu C; Lai G; Leung L; Tse S; Einolf HJ; Wang YH; Sinz M; Stearns R; Walsky R; Geng W; Sudsakorn S; Moore D; He L; Wahlstrom J; Keirns J; Narayanan R; Lang D; Yang X;
    Drug Metab Dispos; 2016 Aug; 44(8):1399-423. PubMed ID: 27052879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.